What is the method of administration for Incruse Ellipta?

Incruse Ellipta is a medication used to help manage chronic obstructive pulmonary disease (COPD) and is administrated as a dry powder. This means that it is delivered in a form that is inhaled directly into the lungs, rather than administered as a liquid, injectable solution, or aerosol spray.

The design of the Ellipta inhaler allows for a precise dose of medication to be released as a dry powder when the patient inhales. This method of delivery is advantageous for respiratory conditions as it ensures that the medication goes directly to the site of action in the airways, leading to improved efficacy and quicker relief of symptoms.

The dry powder formulation also helps to enhance the stability of the medication and can lead to fewer side effects compared to liquid solutions. Furthermore, the inhalation technique with the dry powder inhaler is relatively easy for patients to learn, promoting better adherence to treatment.